# CRX - Project

> **NIH NIH P30** · UNIVERSITY OF VIRGINIA · 2024 · $46,771

## Abstract

CANCER THERAPEUTICS (CRX) – PROJECT SUMMARY/ABSTRACT
 Recent advances offer unprecedented opportunities to create new modes of diagnosing, imaging, and
treating many types of cancer. The Cancer Therapeutics (CRX) Program exists to bring together University of
Virginia Cancer Center (UVACC) investigators whose multi-disciplinary research programs collectively support
preclinical science, validation of therapeutic targets, and translation of discoveries into investigator-initiated
clinical trials (IITs). A hallmark of the CRX program is to drive discoveries and new technologies along the
Translational Pipeline to obtain the UVACC's ultimate goal of reducing the burden of cancer in the catchment
area and beyond. In addition to identifying immune therapeutic targets and developing immunotherapies (Aim
1), CRX advances other therapeutic and imaging discoveries, including those from the Cancer Biology (CBIO)
and Molecular Genetics and Epigenetics (GEN) Programs through preclinical development (Aim 2) culminating
in the initiation and performance of investigator-initiated clinical trials (IITs) of agents developed by UVA
investigators (Aim 3). The CRX program is led by three co-leaders (Slingluff, Kelly, Landen) with
complementary expertise in discovery science, translation, and clinical trials. The Program consists of 59
Members, 29 of whom are new to UVA or the UVACC since the prior renewal, from 16 departments and two
schools. CRX Program Members lead the newly created Translational Research Teams, which facilitate the
productive collaboration of members from all Programs to focus research efforts on four cancers identified to
be particularly burdensome within the catchment area. CRX Members are principal investigators of grants
totaling $5.54M of direct-cost peer-reviewed funding, $3.85M from NCI and $1.69M from other peer-reviewed
sources. CRX depends on infrastructure created by the UVACC, especially the Molecular and Immunological
Translational Sciences Core, Biorepository and Tissue Research Facility, Biostatistics Shared Resource, and
the Office of Clinical Research. Together, these activities culminated in 407 selected publications since the last
renewal. Of these, 25% have an impact factor of 10 or greater, 27% are intra-programmatic, 21% are inter-
programmatic with other UVACC Programs, and 46% are collaborative with other NCI Cancer Centers.

## Key facts

- **NIH application ID:** 10766147
- **Project number:** 5P30CA044579-33
- **Recipient organization:** UNIVERSITY OF VIRGINIA
- **Principal Investigator:** Craig Lee Slingluff
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $46,771
- **Award type:** 5
- **Project period:** 1997-09-16 → 2027-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10766147

## Citation

> US National Institutes of Health, RePORTER application 10766147, CRX - Project (5P30CA044579-33). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10766147. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*